Provided by Tiger Fintech (Singapore) Pte. Ltd.

Reviva Pharmaceuticals Holdings, Inc.

0.8827
-0.0073-0.82%
Volume:312.10K
Turnover:278.97K
Market Cap:41.26M
PE:-0.98
High:0.9179
Open:0.8900
Low:0.8691
Close:0.8900
Loading ...

Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and Reviva Pharmaceuticals Holdings (RVPH)

TIPRANKS
·
10 Jan

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

GlobeNewswire
·
07 Jan

RVPH: Preliminary OLE Readout

Zacks Small Cap Research
·
23 Dec 2024

BRIEF-Applied Therapeutics Appoints John H. Johnson As Executive Chairman

Reuters
·
20 Dec 2024

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

THOMSON REUTERS
·
20 Dec 2024

Applied Therapeutics Inc - Les Funtleyder Appointed Interim CEO

THOMSON REUTERS
·
20 Dec 2024

Applied Therapeutics Inc - Shoshana Shendelman Steps Down as CEO

THOMSON REUTERS
·
20 Dec 2024

Reviva Pharmaceuticals Strengthens Financial Position with Offering

TipRanks
·
19 Dec 2024

Top Midday Decliners

MT Newswires Live
·
18 Dec 2024

Reviva Pharmaceuticals Shares Slide Premarket After Stock Offering

Dow Jones
·
17 Dec 2024

Reviva Pharmaceuticals Prices $18 Million Public Offering

MT Newswires Live
·
17 Dec 2024

BRIEF-Reviva Prices $18 Mln Public Offering Of Common Stock And Warrants

Reuters
·
17 Dec 2024

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

THOMSON REUTERS
·
17 Dec 2024

Reviva Pharmaceuticals Holdings, Inc. - Offering Price $1.50 per Share With Series a and B Warrants

THOMSON REUTERS
·
17 Dec 2024

Reviva Pharmaceuticals Holdings, Inc. - Prices Public Offering of 12 Mln Shares

THOMSON REUTERS
·
17 Dec 2024

Press Release: Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

Dow Jones
·
17 Dec 2024

Reviva Pharmaceuticals announces common stock, warrant offering, no amount given

TIPRANKS
·
17 Dec 2024

Reviva Announces Proposed Public Offering

THOMSON REUTERS
·
17 Dec 2024

Reviva Announces Proposed Public Offering

GlobeNewswire
·
17 Dec 2024

Reviva Pharmaceuticals Reports Positive Topline Phase 3 Data on Brilaroxazine for Treating Schizophrenia

MT Newswires Live
·
16 Dec 2024